Full Press Release Details
BridgeBio Pharma Announces Positive Topline Results From Phase 3 ATTRibute-CM Study.
BBIO
BridgeBio Pharma Announces Positive Topline Results From Phase 3 ATTRibute-CM Study
Key Takeaway: BridgeBio Pharma Announces Positive Topline Results From Phase 3 ATTRibute-CM Study
Price reaction · baseline $18.22 (2023-07-14 close) · 1 other BBIO headline(s) in the window, move may be shared
day 0 close
+75.9%
day 1
+78.5%
day 3 · peak
+89.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis